An MD An­der­son study points to an­oth­er use for No­var­tis’ GSK-born can­cer drugs

5 years ago
R&D

Chi­nook rais­es $106M in pri­vate place­ment as it pre­pares to close merg­er with Aduro

5 years ago
Financing

The End­points 11 cel­e­brates bio­phar­ma's most promis­ing star­tups. Live event on Sep­tem­ber 30

5 years ago
Publisher's note

Look­ing to ex­pand be­yond di­a­betes, No­vo Nordisk en­lists Evotec in CKD pact worth up to $179M per pro­gram

5 years ago
Deals

Eli Lil­ly is bet­ting $1B-plus that it can make yet an­oth­er PD-1 drug a hit in the US. How about a deep dis­count this ...

5 years ago
R&D

As­traZeneca is chang­ing up dos­ing reg­i­mens of its check­point play­er in the face of the pan­dem­ic. The FDA ap­pears ...

5 years ago
R&D
FDA+

Court hands No­var­tis win in Gilenya patent fight; US states seek $26B+ in opi­oid cri­sis law­suit

5 years ago
News Briefing

Mer­ck pre­pares to fi­nal­ly break ground on $1.3B Lon­don re­search hub

5 years ago
R&D
Pharma

Covid-19 roundup: In­side CTAP: 270 tri­als un­der­way, 570+ in the FDA line; WHO chief calls out 'vac­cine na­tion­al­is­m'

5 years ago
Coronavirus

New­ly ar­rived on Nas­daq, Po­sei­da qui­et­ly sig­nals a clin­i­cal hold trig­gered by a pa­tient death in PhI — shares ...

5 years ago
R&D
FDA+

Daniel O’Day’s I/O dance con­tin­ues, as Gilead and Tan­go ex­pand deal up to $6B

5 years ago
Deals
Cell/Gene Tx

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

5 years ago
R&D
FDA+

FDA slaps clin­i­cal hold on Ap­plied Ther­a­peu­tics af­ter sav­age fight over short at­tack

5 years ago
FDA+

KKR health­care vet Jim Mom­tazee jump starts a new in­vest­ment firm; Bay­er signs up a top Chi­na biotech play­er to $645M ...

5 years ago
News Briefing

Black­stone fi­nal­izes R&D pact with Al­ny­lam as part of ear­li­er $2 bil­lion in­vest­ment

5 years ago
Deals
R&D

Taysha buys clin­ic-ready gene ther­a­py from Abeona, bring­ing Steven Gray's port­fo­lio back in one place

5 years ago
Deals
Cell/Gene Tx

In blow to an­ti-ag­ing field, Uni­ty Biotech­nol­o­gy fails first ma­jor study, cuts lead pro­gram

5 years ago
R&D

Teamed up with Lyell, Juno/WuXi joint ven­ture files IPO bet­ting on Chi­na's CAR-T fu­ture

5 years ago
Financing
China

Covid-19 roundup: Just how much is the ‘first wave’ mar­ket for Covid-19 vac­cines worth? One top an­a­lyst sets the ...

5 years ago
Coronavirus

Bris­tol My­ers bets $475M cash on a block­buster shot at break­ing the mold in im­muno-on­col­o­gy — with a po­ten­tial ...

5 years ago
Deals

How bad­ly does Sanofi chief Paul Hud­son want Prin­cip­ia? Enough to ink a $3.7B buy­out deal, dou­bling down on MS

5 years ago
Deals

FDA ap­proves the third NMOSD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal ...

5 years ago
R&D
FDA+

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

5 years ago
R&D
Coronavirus

Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

5 years ago
Deals
R&D
First page Previous page 811812813814815816817 Next page Last page
A service from the Financial Times